Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)

Cancer

Volumn 116, Issue 9, 2010, Pages 2258-2265

  De Camargo, Veridiana Pires ^a   Keohan, Mary L ^a   D'Adamo, David R ^a   Antonescu, Cristina R ^a   Brennan, Murray F ^a   Singer, Samuel ^a   Ahn, Linda S ^a   Maki, Robert G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Anthracycline; Chemotherapy; Deep fibromatosis; Desmoid tumor; Hormonal therapy; Imatinib; Retrospective analysis; Systemic therapy

Indexed keywords

ANTHRACYCLINE; DACARBAZINE; DOXORUBICIN; IBUPROFEN; IMATINIB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SULINDAC; TAMOXIFEN; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARDIOMYOPATHY; CONTROLLED STUDY; DESMOID TUMOR; FEMALE; GARDNER SYNDROME; HEART PAPILLARY MUSCLE DYSFUNCTION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUSCLE DISEASE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; FEMALE; FIBROMATOSIS, AGGRESSIVE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 77951429363     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25089     Document Type: Article

References (23)

1. Alman BA, Pajerski ME, Diaz-Cano S, Corboy K, Wolfe HJ. Aggressive fibromatosis (desmoid tumor) is a monoclonal disorder. Diagn Mol Pathol. 1997;6:98-101. (Pubitemid 27155030)
2. Lewis JJ, Boland PJ, Leung DH, Woodruff JM, Brennan MF. The enigma of desmoid tumors. Ann Surg. 1999;229: 866-872.
3. Hosalkar HS, Torbert JT, Fox EJ, Delaney TF, Aboulafia AJ, Lackman RD. Musculoskeletal desmoid tumors. J Am Acad Orthop Surg. 2008;16:188-198.
4. Nieuwenhuis MH, De Vos Tot Nederveen Cappel W, Botma A, et al. Desmoid tumors in a dutch cohort of patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol. 2008;6:215-219. (Pubitemid 351172943)
5. Bertario L, Russo A, Sala P, et al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol. 2003;21:1698-1707. (Pubitemid 46638580)
6. Clark SK, Neale KF, Landgrebe JC, Phillips RK. Desmoid tumours complicating familial adenomatous polyposis. Br J Surg. 1999;86:1185-1189. (Pubitemid 29427837)
7. Lev D, Kotilingam D, Wei C, et al. Optimizing treatment of desmoid tumors. J Clin Oncol. 2007;25:1785-1791.
8. Bonvalot S, Eldweny H, Haddad V, et al. Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients. Eur J Surg Oncol. 2008; 34:462-468. (Pubitemid 351381296)
9. Gega M, Yanagi H, Yoshikawa R, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol. 2006;24:102-105. (Pubitemid 46630500)
10. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
11. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92: 205-216.
12. Fong Y, Rosen PP, Brennan MF. Multifocal desmoids. Surgery. 1993;114:902-906.
13. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer. 2004;100:612-620. (Pubitemid 38128287)
14. Patel SR, Evans HL, Benjamin RS. Combination chemotherapy in adult desmoid tumors. Cancer. 1993;72:3244-3247. (Pubitemid 23356767)
15. Heinrich MC, Joensuu H, Demetri GD, et al. Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases. Clin Cancer Res. 2008;14:2717-2725.
16. Heinrich MC, McArthur GA, Demetri GD, et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol. 2006;24:1195-1203. (Pubitemid 46638818)
17. Okuno SH, Edmonson JH. Combination chemotherapy for desmoid tumors. Cancer. 2003;97:1134-1135.
18. Baker LH, Wather K, Chugh R, et al. Activity of imatinib mesylate in desmoid tumors: interim analysis of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial [abstract]. J Clin Oncol. 2004;22(14 suppl):821S. Abstract 9013.
19. Scott RJ, Froggatt NJ, Trembath RC, Evans DG, Hodgson SV, Maher ER. Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3′ APC gene mutation. Hum Mol Genet. 1996;5:1921-1924.
20. Alman BA, Li C, Pajerski ME, Diaz-Cano S, Wolfe HJ. Increased beta-catenin protein and somatic APC mutations in sporadic aggressive fibromatoses (desmoid tumors). Am J Pathol. 1997;151:329-334. (Pubitemid 27330053)
21. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol. 2008;173: 1518-1527.
22. Caspari R, Olschwang S, Friedl W, et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet. 1995;4:337-340.
23. Tejpar S, Nollet F, Li C, et al. Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor). Oncogene. 1999; 18:6615-6620.